XBIO Company Profile and Key Details

XBIO has shown mixed momentum, gaining 8.89% over the past week and -40.62% over the past quarter, though year-to-date performance is up 15.21%. Short-term trend indicators are bullishly aligned (SMA20 7.99%, SMA50 7.24%, SMA200 -20.11%). The stock’s 14-day RSI is 56.17 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.63% below its high and over 27.37% above its low. Average 10-day trading volume of 9.79 thousand shares is below the 3-month average of 22.64 thousand, indicating normal recent market interest.

Xenetic Biosciences, Inc. generated EPS of -$2.05 over the past year. Five-year average earnings growth is 47.32%. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at $nan. Next year's EPS is expected at $77.30. Xenetic Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended March 12, 2026, missed forecasts by -57.69%. The prior quarter beat by -32.65%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 13, 2024.

Xenetic Biosciences, Inc. has 1.54 million shares outstanding. The public float is 1.18 million shares, elevated short interest at 1.51% of float. This equals 22.00 thousand shares. The short ratio is 0.73 days. Institutional investors hold 11.45% of the float. Insiders own 10.24%.

Xenetic Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.07. This means the shares are trading below this model’s fair value.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) closed at $2.97 USD, losing -$0.06 (-1.98%) from the previous close of $3.03. The stock is currently mid-range between its 52-week high and low $1.90 and $13.93. With a market capitalization of about $5.05 million, Xenetic Biosciences, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.21). Key stats such as the average daily volume over the past year has been around 21.56 thousand shares, volume is running light vs its 52-week average. Headquartered in Framingham, MA, Xenetic Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James F. Parslow, the company employs approximately 2 people and listed since June 30, 2016. Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.

Xenetic Biosciences, Inc. trades at a P/E ratio of -2.58, slightly below the S&P 500 average, with a price-to-sales ratio of 1.73 and a price-to-book ratio of 0.94 suggesting the stock is closer to book value. The P/FCF stands at -2.25, also below market averages.

Our AI price prediction model suggests that Xenetic Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.61%, with price expected at $3.20 by May 14, 2026, within a range of $2.93 to $3.47 3-Month Outlook: Projected fall of -5.94%, reaching $2.85 by July 29, 2026, with a range of $2.44 to $3.15. 1-Year Outlook: Projected gain of 129.7%, with price at $6.96 by April 30, 2027, within a range of $2.83 to $8.17.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) shares are up 15.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Xenetic Biosciences, Inc. trading at a premium to the broader market with a P/E of -2.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $3.25, suggesting 7.26% upside. Our AI forecast model points to short-term strength (5.61% over two weeks), a medium-term fall (-5.94% over three months), and a longer-term gain (129.7% over one year), with expected trading ranges indicating moderate volatility.